Oncura

Oncura is a global leader in the field of brachytherapy, specializing in the development and manufacture of radioactive seeds for the treatment of prostate cancer and other malignancies. The company provides a range of Iodine-125 and Palladium-103 products, including the EchoSeed and RapidStrand brands, which are designed to deliver precise, localized radiation directly to tumor tissue. Originally established as a joint venture between GE Healthcare and Amersham, Oncura became a wholly-owned subsidiary of GE Healthcare before being acquired by Merit Medical Systems in 2020. Its technology focuses on minimally invasive oncology treatments, supported by advanced delivery systems and treatment planning software.